PubMed

Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.

Chen C, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E.

Clin Lymphoma Myeloma. 2009 Mar;9(1):74-6. Review.PMID: 19362979 [PubMed - indexed for MEDLINE]Related articles

A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia.

Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM, Szczepiorkowski ZM, AuBuchon JP, Barty RL, Lee KA; SToP Study Investigators of the BEST Collaborative.

Blood. 2009 Feb 12;113(7):1564-73. Epub 2008 Dec 24.PMID: 19109560 [PubMed - indexed for MEDLINE]Related articles

Canadian supportive care recommendations for the management of neutropenia in patients with cancer.

Kouroukis CT, Chia S, Verma S, Robson D, Desbiens C, Cripps C, Mikhael J.

Curr Oncol. 2008 Feb;15(1):9-23.PMID: 18317581 [PubMed - in process]Related articlesFree article

Canadian supportive care recommendations for the management of anemia in patients with cancer.

Mikhael J, Melosky B, Cripps C, Rayson D, Kouroukis CT.

Curr Oncol. 2007 Oct;14(5):209-17.PMID: 17938704 [PubMed - in process]Related articlesFree article

Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria.

Assouline S, Meyer RM, Infante-Rivard C, Connors JM, Belch A, Crump M, Kouroukis CT, Eisenhauer E.

Leuk Lymphoma. 2007 Mar;48(3):513-20.PMID: 17454591 [PubMed - indexed for MEDLINE]Related articles

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 Apr 20;25(12):1570-5. Epub 2007 Mar 12.PMID: 17353550 [PubMed - indexed for MEDLINE]Related articles

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.

Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers J, Wright J, Eisenhauer EA.

Ann Oncol. 2007 Jan;18(1):116-21. Epub 2006 Sep 13.PMID: 16971665 [PubMed - indexed for MEDLINE]Related articlesFree article

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2003 May 1;21(9):1740-5.PMID: 12735303 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma.

Kouroukis CT, O'Brien BJ, Benger A, Marcellus D, Foley R, Garner J, Ingram C, Haines P, Henderson-O'Connor N, Meyer R.

Leuk Lymphoma. 2003 Jan;44(1):29-37.PMID: 12691140 [PubMed - indexed for MEDLINE]Related articles

Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review.

Kouroukis CT, Browman GP, Esmail R, Meyer RM.

Ann Intern Med. 2002 Jan 15;136(2):144-52. Review.PMID: 11790067 [PubMed - indexed for MEDLINE]Related articles

Treatment strategies in elderly patients with aggressive histology lymphoma.

Kouroukis CT, Meyer RM.

Ann Hematol. 2001;80 Suppl 3:B86-8. Review. No abstract available. PMID: 11757717 [PubMed - indexed for MEDLINE]Related articles